Olorinab

DRUG3 trials

Sponsors

Arena Pharmaceuticals

Conditions

Abdominal PainCrohn's DiseaseIrritable Bowel Syndrome

Phase 1

Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome

TerminatedNCT04655599

Arena PharmaceuticalsIrritable Bowel Syndrome

Start: 2021-01-29End: 2021-04-13Updated: 2021-05-17

Phase 2

Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain

CompletedNCT03155945

Arena PharmaceuticalsAbdominal Pain, Crohn's Disease

Start: 2017-07-19End: 2018-09-10Updated: 2021-11-02

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

TerminatedNCT04043455

Arena PharmaceuticalsIrritable Bowel Syndrome

Start: 2019-07-24End: 2021-04-29Updated: 2025-01-30

Related Papers

Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo‐controlled trial (<scp>CAPTIVATE</scp>)

Neurogastroenterology & Motility2023-02-0529 citations